Document is current

Article History

Received: 30 January 2023

Accepted: 7 May 2024

First Online: 11 October 2024

Declarations

:

: The study (internal number V19086) was conducted under the authorized conditions described in the Summary of Product Characteristics of the vaccine Ruvax^® (2524ESP). Experimental protocol was sent it and evaluated by the Spanish Medicines Agency (AEMPS) (application number 20190327/V/25/0001), which is the health licensing institutional body in our country, and it was accepted. The ethics approval was deemed unnecessary according to European and national legislation (Directive 2010/63/EU of the European parliament and RD53/2013). In both regulation state that the ethics approval is not necessary in case of: (a) non-experimental agriculture practices, (b) non-experimental clinical veterinary practices and d) practices undertaken for the purposes of recognized animal husbandry. This study is framed in these assumptions because the procedures carried out are commonly used in the farms. Moreover, Inga Food S.A. (owner of the animals) consented to participate and stated that the study is about the efficacy of different current vaccine protocols in their farms. All their staff are trained to use of the best welfare practices in swine production and part of their veterinarians actively monitored and performed the research.

: Not applicable.

: ES-T, CA, OG-D are employees of Boehringer Ingelheim Animal Health, a partial funder of this study. As author of the study, ES-T, had influence over the study design. However, there was no point at which conclusions or interpretations put forward, that were suggested by ES-T, CA, OG-D, without full agreement of the other authors.